Journal of Medicinal Chemistry · 2021 · 10 citations · 43 references
PharmacyMedicinal ChemistryPharmacologyMolecular VirologyProdrug DesignVirologyAntiviral AgentsAntiviral PharmacologyAntiviral Prodrug DesignAntiviral TherapyNucleotide MetabolismViral InfectionsAntiviral Drug DesignAntiviral TherapeuticsAntiviral TreatmentBroad-spectrum Antiviral AgentsDirect-acting Antiviral AgentsNucleoside AnalogsNucleoside ModificationNucleotide Analogue Prodrugs
The naturally occurring nucleotide 3′-deoxy-3′,4′-didehydro-cytidine-5′-triphosphate (ddhCTP) was recently found to exert potent and broad-spectrum antiviral activity. However, nucleoside 5′-triphosphates in general are not cell-permeable, which precludes the direct use of ddhCTP as a therapeutic. To harness the therapeutic potential of this endogenous antiviral nucleotide, we synthesized phosphoramidate prodrug HLB-0532247 (1) and found it to result in dramatically elevated levels of ddhCTP in cells. We compared 1 and 3′-deoxy-3′,4′-didehydro-cytidine (ddhC) and found that 1 more effectively reduces titers of Zika and West Nile viruses in cell culture with minimal nonspecific toxicity to host cells. We conclude that 1 is a promising antiviral agent based on a novel strategy of facilitating elevated levels of the endogenous ddhCTP antiviral nucleotide.
43
Michael J. Sofia, Donghui Bao, Wonsuk Chang et al. · Journal of Medicinal Chemistry · 2010 · 620 citations
William A. Lee, Gong-Xin He, Eugene Eisenberg et al. · Antimicrobial Agents and Chemotherapy · 2005 · 339 citations · Full text
A naturally occurring antiviral ribonucleotide encoded by the human genome
Anthony S. Gizzi, Tyler L. Grove, Jamie J. Arnold et al. · Nature · 2018 · 333 citations
Peter Ruane, Edwin DeJesus, Daniel Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 307 citations